Overview
BlueRock Therapeutics is a clinical-stage cell therapy company developing regenerative medicines to address degenerative diseases across neurology, cardiology, ophthalmology, and immunology. The company leverages proprietary technology for manufacturing pluripotent stem cells at scale, combined with advanced gene editing capabilities to engineer therapeutic cells with enhanced function. BlueRock's approach targets fundamental cellular loss and dysfunction by replacing damaged or lost cells rather than managing symptoms, with lead programs in Parkinson's disease and inherited retinal diseases. As a wholly-owned subsidiary of Bayer AG, the company operates independently while benefiting from Bayer's resources and expertise in cell and gene therapy development.